Hepatitis C is a viral infection that damages the liver. Direct-acting antivirals (DAAs) introduced in the past decade cure more than 95% of people treated, typically with 8-12 weeks of pills and minimal side effects. Current research focuses on reaching the millions of people worldwide who remain undiagnosed or untreated, and on preventing liver damage in those with advanced disease.
What's actually going on in research
Trials are testing shorter treatment courses, pan-genotypic regimens that work regardless of virus strain, single-tablet combinations, and delivery methods for populations with limited healthcare access. Researchers are also studying treatments for advanced liver scarring, strategies to find undiagnosed cases, and whether curing hepatitis C reduces liver cancer risk in people with cirrhosis.
Shorter treatment courses
Studies are testing whether 4-6 weeks of DAAs can cure hepatitis C as effectively as current 8-12 week regimens. Shorter courses could improve completion rates and reduce cost.
Access and diagnosis
Trials are testing point-of-care testing, same-day treatment initiation, and decentralized care models to reach people who inject drugs, incarcerated populations, and communities with limited healthcare infrastructure. Finding and treating undiagnosed cases is now the main barrier to eliminating hepatitis C.
Liver disease management
Research is examining whether DAA cure reverses liver scarring and reduces cancer risk in people with cirrhosis. Studies are also testing whether antiviral therapy should be combined with treatments targeting liver inflammation and fibrosis.
What to know before you search
Eligibility typically depends on hepatitis C genotype, degree of liver scarring, prior treatment history, and presence of other liver diseases or HIV co-infection.
What types of trials are currently open
- Treatment duration trials — Testing whether shorter courses of DAAs (4-6 weeks instead of 8-12) can cure hepatitis C in people with early-stage disease or specific genotypes.
- Simplified regimen trials — Testing single-tablet combinations and pan-genotypic regimens that eliminate the need for genotype testing before treatment.
- Access trials — Testing models of care that bring diagnosis and treatment to underserved populations, including same-day treatment and community-based programs.
- Post-cure trials — Following people after successful treatment to measure liver disease progression, cancer risk, and whether scarring reverses.
- Prevention trials — Testing strategies to prevent reinfection in people who inject drugs and other high-risk populations.
Recently added Hepatitis C trials
Try a team-based care approach for hepatitis C treatment
The objective of this study is to extend our prior research by conducting a pragmatic implementation trial using a parallel-group, cluster randomized design to evaluate the PPP-CCM's ability to improve access to DAAs for HCV within a network of permanent supportive housing (PSH) buildings in Seattle and King County. The study will implement PPP-CCM to 16 housing buildings, randomizing half to receive PPP-CCM (intervention) versus usual care (UC) for 12-months, after which all buildings will have access to PPP-CCM. All buildings will have access to point-of-care HCV screening for the first 6 months of the study. Study outcome data will be collected through a longitudinal cohort-study of persons who screened positive for HCV which will conduct surveys and review of medical records at baseline, 12- and 24-months.
Take a nutritional supplement to support liver health
The purpose of this clinical trial is to evaluate whether a nutritional supplement containing resveratrol, quercetin, taurine, inulin, and whey protein improves biochemical and molecular markers, as well as clinical outcomes, in patients with liver disease related to chronic hepatitis C infection. The study will compare the investigational supplement with an active control (whey protein alone) to determine whether the combination formulation provides additional benefits on liver-related biomarkers and clinical assessment. Participants will: Take the investigational supplement or active control daily for 12 weeks. Attend clinic visits every 4 weeks for laboratory testing and clinical evaluations.
Find Hepatitis C trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.